Royal Lifescience Corp. Announces Update on Its Qualifying Transaction
ROYAL LIFESCIENCE CORP.
1780 – 400 Burrard Street
Vancouver, British Columbia V6B 3K1
NEWS RELEASE
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE
UNITED STATES
Royal Lifescience Corp. Announces Update on Its Qualifying Transaction
May 2, 2018 NEX Board of the TSX Venture Exchange
Trading Symbol: RLS.H
Vancouver, BC – Royal Lifescience Corp. (the “Company”), a capital pool company pursuant to Policy
2.4 of the TSX Venture Exchange (the “Exchange”), is pleased to announce that further to its press
releases dated November 22, 2017 and January 10, 2 018, the Exchange has conditionally approved its
qualifying transaction (the “QT”), subject to the Exchange’s receipt of final documentation of the
Company. Pursuant to the terms of the QT, the Company proposes, among other matters, to amalgamate
with Rover Metals Corp. (“Rover” and “Amalgamation” respectively) under the Business Corporations
Act (British Columbia) and continue as an amalgamated British Columbia entity (the “Resulting Issuer”).
As a result of the Amalgamation, Royal will effectively acquire Rover through the issuance of 32,377,000
common shares in the capital of the Resulting Issuer at a deemed price of $0.125 per Resulting Issuer
share for aggregate deemed consideration of $4,047,125, exclusive of the Resulting Issuer shares to be
issued pursuant to the concurrent financing (the “Concurrent Financing”) to be undertaken by Rover
prior to or concurrently with the Amalgamation. The Concurrent Financing contemplates Rover raising
aggregate gross proceeds of a minimum of $1,137,500 and up to a maximum of $4,807,220 (or such other
amount as may be agreed to between Royal and Rover prior to closing of the Concurrent Financing), via
the issuance of a minimum of 9,100,000 units of Rover (each a “Unit”) and up to a maximum of
36,051,571 Units of Rover (or such additional number as may be issued under the Concurrent Financing).
Each Unit of Rover can either (i) be at a price of $0.125 per Unit and consist of one Rover common share
and one Rover common share purchase warrant exercisable into one Rover common share at $0.25 for a
period of 12 months following the date of issuance and at an exercise price of $0.50 for the period
commencing 12 months following the date of issuance and ending 24 months following the date of
issuance, or (ii) be at a price of $0.14 per Unit and consist of one Rover flow-through common share and
one Rover common share purchase warrant exercisable into one Rover common share at an exercise price
of $0.28 for a period of 12 months following the date of issuance and at an exerc ise price of $0.56 for the
period commencing 12 months following the date of issuance and ending 24 months following the date of
issuance.
As part of the QT, certain directors and officers of both Rover and the Company have entered into
voluntary support agreements with the Company and Rover respectively, pursuant to which they have
agreed, among other things, to support the Amalgamation in their capacity as Rover shareholders or
Company’s shareholders, as applicable, and vote their shares in favour of the Amalgamation.
The Company is also pleased to announce that it has mailed an information circular dated April 30, 2018
(the “Circular”) to its shareholders in connection with an annual and special meeting of the Company’s
shareholders to be held on May 30, 2018 (the “Meeting”). At the Meeting, the shareholders will be
asked, among other matters, to approve the Company's QT with Rover. A copy of the Circular is
available under the Company’s SEDAR profile at www.sedar.com.
Trading in the common shares of the Company will continue to remain halted and will recommence at
such time as the TSXV may determine based on the satisfaction of certain requirements pursuant to
TSXV Policy 2.4.
ROYAL LIFESCIENCE CORP.
1780 – 400 Burrard Street
Vancouver, British Columbia V6B 3K1
About the Company
The Company is d esignated as a Capital Pool Company by the Exchange. The Company has not
commenced commercial operations and has no assets other than cash. The only business of the Company
is the identification and evaluation of assets or businesses with a view to complet ing a "Qualifying
Transaction" in accordance with Exchange Policy 2.4 - Capital Pool Companies.
On behalf of the Board of Directors
Minaz Dhanani
Chief Executive Officer, Chief Financial Officer, Director
For further information please contact:
Minaz Dhanani
Telephone: (604) 783-7361
Cautionary Statements
All information contained in this news release with respect to the Company and Rover was supplied by
the parties, respectively, for inclusion herein, and the Company and its directors and officers hav e relied
on Rover for any information concerning Rover.
Completion of the QT is subject to a number of conditions, including but not limited to, Exchange final
acceptance and if applicable pursuant to Exchange requirements. The QT cannot close until the required
shareholder approval is obtained. There can be no assurance that the QT will be completed as proposed
or at all. Investors are cautioned that, except as disclosed in the Circular prepared in connection with the
transaction, any information released or received with respect to the transaction may not be accurate or
complete and should not be relied upon. Trading in the securities of a capital pool company should be
considered highly speculative.
The Company common shares have not been and will not be registered under the United States Securities
Act of 1933, as amended and may not be offered or sold in the United States absent registration or an
applicable exemption from the registration requirement. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful.
This news release contains forward -looking statements relating to the timing and c ompletion of the QT,
the future operations of the Company and other statements that are not historical facts. Forward -looking
statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and
similar expressions. All sta tements other than statements of historical fact, included in this release,
including, without limitation, statements regarding the QT and the future plans and objectives of the
Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance
that such statements will prove to be accurate and actual results and future events could differ materially
from those anticipated in such statements. Important factors that could cause actual results to differ
materially from the Company's expectations include the failure to satisfy the conditions to completion of
the QT set forth above and other risks detailed from time to time in the filings made by the Company with
securities regulations
Neither the TSX Venture Exchange not its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.